stockrow
Friday 6 November 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
121.14
2.01
+1.69%
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) Free cash flow
GRAIL, Inc.'s free cash flow for fiscal 2025 was −$299.9M, compared with −$582.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$312.0M. GRAIL, Inc. ranks 49th of 49 Diagnostics & Research companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$299.9M | — |
| FY2024 | −$582.4M | — |
| FY2023 | −$608.7M | — |
| FY2022 | −$584.2M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$79.5M | — |
| Jun 2026 | −$81.2M | — |
| Mar 2026 | −$87.5M | — |
| Dec 2025 | −$63.9M | — |
| 11 more quarters | Free account |
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ICLR ICON PLC compare | $857.1M |
| QGEN QIAGEN N.V. compare | $440.6M |
| VCYT Veracyte, Inc. compare | $161.9M |
| SHC Sotera Health Company compare | $135.4M |
| RDNT RadNet, Inc. compare | $74.4M |
| CDNA CareDx, Inc. compare | $59.8M |
| BLLN BillionToOne, Inc. compare | $33.9M |
| ADPT Adaptive Biotechnologies Corporation compare | −$8.8M |
| GRAL GRAIL, Inc. | −$312.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on GRAL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement